Guangzhou Kingmed Diagnostics: Post-IPO Transformation

內容大綱
Guangzhou KingMed Diagnostics was the leading third-party independent clinical laboratory in China. On the eve of the Lunar New Year in 2020, the chairman and CEO of Guangzhou KingMed Diagnostics mobilized the whole group to respond to the outbreak of the new coronavirus from Wuhan. With the group’s tremendous growth in both business and size since its initial public offering, there were growing concerns about the provision of quality customer service and the group’s profitability. While the chairman and CEO was proud to see how swiftly his team had responded to the COVID-19 pandemic, he had many questions about the efficiency of the entire group's resource deployment and the consistency of performance across subsidiaries. Post COVID-19, how should Guangzhou KingMed Diagnostics adjust its transformation strategy?
學習目標
The case can be used in undergraduate-, graduate-, and executive-level courses on operations management, and in service management with an emphasis on health care operations. The case is best used for discussing the much-needed transformation of a company (an industry leader, in this case) to maintain its competitiveness in an increasingly competitive industry landscape with many start-ups and new entrants.<br><br>This case details how KingMed pioneered, grew, and became the leading independent clinical laboratory in China. It highlights the challenges KingMed faced in its daily operations. Students have the opportunity to study data provided by the company to develop analytical insights into the key issues. The case encourages students to analyze the profitability of a business from a service-chain perspective. After working through the case and assignment questions, students should be able to do the following:<ul><li>Analyze the fundamentals for profitability in KingMed’s business model.</li><li>Analyze the different challenges KingMed faced after its IPO.</li><li>Assess KingMed’s state of competitiveness at the time of the COVID-19 pandemic.</li><li>Identify actions to improve KingMed’s competitiveness.</li><li>Propose a strategy and an action plan for KingMed’s post-COVID-19 transformation.</li></ul>
涵蓋主題
新增
新增